CLINICAL_TRIALS
trial_result
· 2017-05-10
Clinical Trial Update: Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis [Phase 2]
Summary
Phase 2 trial is terminated for idelalisib in IgM-associated primary (AL) amyloidosis; results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: John Mark Sloan | Conditions: Amyloidosis | Phase 2 | Status: TERMINATED | Results posted: 2017-05-10